Financial Data and Key Metrics Changes - The company reported record revenue of $19.2 million for Q4 2025, a 35% increase from $14.2 million in the same period last year [6][25] - Gross profit for Q4 2025 increased to $12 million compared to $9 million in the prior year, while gross profit margin slightly decreased to 62.6% from 63% [29] - Net loss attributable to stockholders was $1.3 million or $0.03 per share for Q4 2025, compared to a net loss of $4.6 million or $0.12 per share in the prior year [31] Business Line Data and Key Metrics Changes - Revenue for the surgical aesthetics segment increased 38% to $16.7 million in Q4 2025, driven by sales of the AYON body contouring system [26][27] - OEM segment sales increased 16% to $2.5 million in Q4 2025, attributed to increased sales volume to existing customers [28] Market Data and Key Metrics Changes - Domestic revenue increased 42% year-over-year to $15 million, while international revenue increased 15% year-over-year to $4.2 million [28] - The market for aesthetic surgery is evolving, with a notable increase in demand driven by the adoption of GLP-1 drugs for weight loss, leading to increased interest in body contouring treatments [16][18] Company Strategy and Development Direction - The company is focused on expanding the AYON platform and enhancing its market position by acquiring high-caliber sales talent [21][65] - Plans to submit for regulatory approvals in key international markets, including Europe and Brazil, are underway to expand AYON's reach [71] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong market demand for AYON and the potential for significant growth in the aesthetic surgery market [9][20] - The company anticipates total revenue for 2026 to be in the range of $57.5 million to $58.5 million, reflecting a 9%-11% increase compared to 2025 [35] Other Important Information - Cash used in operating activities decreased to $2.5 million in Q4 2025 from $2.9 million in the prior year, and for the full year, cash used decreased to $8 million from $18.7 million [32][33] - The company expects to achieve cash flow positivity no later than Q4 2026 [80] Q&A Session Summary Question: Can you provide more details on handpiece and capital equipment sales? - Management indicated that growth in Q4 was driven by AYON, with domestic sales growing nearly 50% [47] Question: What is the pricing strategy for AYON? - The list price for AYON is approximately $360,000, which includes the Apyx One generator and complementary components [50] Question: What feedback have you received from customers regarding AYON? - Customers have expressed strong satisfaction with AYON, with requests for the power-assisted handpiece expected in the first half of the year [54] Question: How are new salespeople being integrated into the company? - The company is leveraging the strength of AYON to attract top sales talent and is focusing on expanding market share [62][65] Question: What are the plans for AYON's international expansion? - Currently approved only in the U.S., the company plans to register AYON in key international markets, including Europe and Brazil [71]

Group 1 - AirSculpt Technologies, Inc. will participate in the Sidoti Micro Cap Conference virtually on August 20-21, 2025, with a presentation scheduled for 10:00am ET on August 20 [1] - The presentation will be available for live webcast and archived for 90 days [1] Group 2 - AirSculpt offers a next-generation body contouring treatment that is minimally invasive, designed to remove fat and tighten skin while allowing for quick healing and minimal bruising [2] - The procedure aims to provide precise results in sculpting targeted areas of the body [2]